(January 20, 2017) OCRFA has awarded $5.6 million in new scientific research grants for ovarian cancer, bringing our total investment in life-saving research to over $75 million. This year’s grants … Continued
(Dec. 21, 2016) Research published recently in Cancer Discovery suggests that cells in the fallopian tube previously thought to be precursors to high grade serous ovarian cancer may sometimes be … Continued
(Dec. 19, 2016) The U.S. Food and Drug Administration today granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer. Rubraca is approved for … Continued
OCRFA-funded scientists are working hard to save women’s lives. In medical institutions across the country, they investigate the origins and biology of ovarian cancer, find new ways to identify and … Continued
(Dec. 9, 2016) This week Genentech announced that the US Food and Drug Administration has expanded approval for bevacizumab (Avastin) to include patients with platinum-sensitive, recurrent disease, either in combination … Continued
Recurrence is in the back of every ovarian cancer survivor’s mind. In this presentation, originally broadcast on November 28, 2016, Dr. Sarah Adams provided an overview of strategies for managing … Continued
(Nov. 3, 2016) Senescence is the state when normal, healthy cells no longer have the ability to divide, which can occur during chemotherapy or when cancer genes within that cell … Continued
(October 31, 2016) Estrogen signaling is a known factor in how certain estrogen receptive (ER positive) tumors grow in breast and ovarian cancers. That signaling, which can promote malignant tumor … Continued
On September 7th, the FDA issued an important safety communication about tests marketed as ovarian cancer screening tests, including the ROCA Test developed by Abcodia Incorporated. The FDA states, “despite extensive … Continued
A Mayo Clinic research team has found evidence suggesting that premenopausal women who are not at high risk of ovarian cancer should not have their ovaries removed for the purpose … Continued
(October 11, 2016) According to research published this month in the New England Journal of Medicine, the PARP inhibitor niraparib improves progression free survival in recurrent, platinum-sensitive women both with … Continued
Meet a Researcher: We had the chance to interview Dr. Hui Shen, a 2016 Liz Tilberis Early Career Award grantee to get to know her! Read our interview here. OCRFA: … Continued
Get email updates about research news, action alerts, and ways to join the fight.
